Publication | Open Access

Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial

NanomedicineUrologyMedicineMetronomic TherapyPharmacologyNanoparticle–drug Conjugate Crlx101Tumor TargetingCancer TreatmentOncology